ClinicaliQ Trial Snapshot
- An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia — Recruiting • Phase II • NCT06712823.
- Long-term study testing whether atumelnant is safe and effective for treating congenital adrenal hyperplasia.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894). Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia Interventions: atumelnant (CRN04894) Lead Sponsor: Crinetics Pharmaceuticals Inc. Planned Enrollment: 200 participants